Zevra Therapeutics Reports Significant Turnaround in 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy ZVRA?
Source: NASDAQ.COM
- Revenue Surge: Zevra Therapeutics reported a net revenue of $34.1 million in Q4 2025, nearly tripling from $12.0 million in Q4 2024, indicating strong market demand for its rare disease therapy MIPLYFFA, which is expected to further drive future revenue growth.
- Profitability Recovery: The company achieved a net income of $12.2 million in 2025, or $0.20 per share, compared to a net loss of $35.7 million, or $0.67 per share in 2024, reflecting the successful launch of MIPLYFFA and contributions from other products, marking a significant improvement in financial health.
- Portfolio Expansion: MIPLYFFA contributed $87.4 million in revenue in 2025, up from $10.1 million in 2024, while OLPRUVA's revenue increased from $0.1 million to $0.8 million, demonstrating the company's ongoing growth potential in the rare disease sector.
- R&D Progress: Zevra is advancing Celiprolol in clinical trials, which has received Orphan Drug and Breakthrough Therapy designations from the FDA, with 52 patients enrolled by year-end 2025, expected to accelerate its market launch and enhance the company's product line.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.120
Low
21.00
Averages
24.00
High
26.00
Current: 9.120
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Reports Q4 Earnings Exceeding Expectations
- Revenue Surge: Zevra Therapeutics reported Q4 net revenue of $34.1 million, surpassing analyst expectations of $28.05 million, indicating strong market performance in treating Niemann-Pick disease.
- Earnings Reversal: The company achieved a diluted earnings per share of $0.19, a significant turnaround from a loss of $0.67 in the same quarter of 2024, exceeding the analyst estimate of $0.05, reflecting a notable improvement in profitability.
- Strong Cash Reserves: At year-end, Zevra held $238.9 million in cash, cash equivalents, and securities, which is expected to be sufficient to execute its strategic priorities independently of capital markets, enhancing financial stability.
- Market Sentiment Shift: Retail sentiment around ZVRA stock on Stocktwits shifted from 'bullish' to 'extremely bullish', with analysts unanimously rating it 'Buy' and a 12-month price target of $22.54, indicating strong market confidence in its growth prospects.
See More
Zevra Therapeutics Surges 21% After Strong Earnings Report
- Strong Earnings: Zevra Therapeutics reported over $34 million in net revenue for Q4 2025, a 44% increase year-over-year, significantly exceeding analysts' expectations of $28 million, indicating robust market performance and growth potential.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a remarkable turnaround from a $35.7 million loss in the previous year, enhancing investor confidence in its financial health.
- Miplyffa Sales Surge: Miplyffa's net sales skyrocketed to over $87 million in the quarter, nearly ninefold growth compared to last year, reflecting strong market acceptance for treating Niemann-Pick disease and driving overall company performance.
- International Market Potential: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating significant expansion potential in international markets, which could further bolster the company's growth trajectory.
See More
Zevra Therapeutics Reports 44% Revenue Growth and Profitability
- Financial Performance Exceeds Expectations: Zevra Therapeutics reported over $34 million in net revenue for Q4, reflecting a 44% year-over-year increase that significantly surpassed analyst expectations of $28 million, indicating robust market performance and a notable improvement in profitability.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a substantial turnaround from a loss of $35.7 million in the same quarter last year, which enhances investor confidence in the company's financial health.
- Miplyffa Drug Success: Miplyffa's net sales soared to nearly $87 million this quarter, nearly ninefold growth compared to last year, with coverage reaching 68% of lives, demonstrating strong market acceptance and potential in treating Niemann-Pick disease.
- International Market Opportunities: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating that the drug's success in the U.S. could be replicated in the European market, further expanding the company's growth prospects.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
Zevra Therapeutics Stock Rises 19% Following GeneDx Testing Program Announcement
- Significant Stock Surge: Zevra Therapeutics (ZVRA) shares have surged approximately 19% in Tuesday morning trading, currently priced at $10.83, reflecting an 18.75% increase from the opening price of $9.12, indicating strong market enthusiasm for the new initiative.
- New Genetic Testing Initiative: GeneDx has announced a collaboration with Zevra to launch a new genetic testing program aimed at expanding access to exome sequencing for Niemann-Pick Disease type C, assisting clinicians in confirming diagnoses and guiding clinical decisions.
- Trading Range Insights: Over the past year, Zevra's stock has fluctuated between $6.19 and $13.16, with the current price nearing its yearly high, showcasing investor confidence in the company's growth potential moving forward.
- Patient Benefits: Through this program, eligible patients in the United States will gain access to genomic testing to help confirm or rule out a diagnosis of Niemann-Pick Disease type C, thereby enhancing treatment outcomes and quality of life for patients.
See More
U.S. Stocks Rise as NIO Reports Strong Earnings
- Quarterly Revenue Surge: NIO reported quarterly revenue of 34.65 billion yuan ($4.95 billion), reflecting a year-over-year increase of 75.9% and a sequential rise of 59.0%, surpassing the analyst consensus estimate of $4.61 billion, indicating robust market demand and sales growth potential.
- Significant Earnings Improvement: The company's adjusted earnings came in at 0.29 yuan (4 cents) per ADS, a remarkable turnaround from a loss of 3.17 yuan per ADS a year earlier, exceeding expectations for a 5-cent loss, showcasing effective cost control and enhanced profitability.
- Stock Price Rally: Following the earnings report, NIO shares surged 10.6% to $5.47, reflecting investor optimism regarding the company's future growth prospects and potentially attracting more institutional investor interest.
- Overall Market Performance: The U.S. stock market rose overall, with the Dow Jones index gaining around 200 points on Tuesday, indicating increased confidence in economic recovery, which may provide a favorable investment environment for NIO and other tech stocks.
See More
Zevra Reports Q4 Earnings Exceeding Expectations
- Revenue Surge: Zevra Therapeutics reported Q4 net revenue of $34.1 million, surpassing analyst expectations of $28.05 million, indicating strong market performance in treating Niemann-Pick disease.
- Earnings Reversal: The company achieved a diluted earnings per share of $0.19, a significant turnaround from a loss of $0.67 in the same quarter of 2024, exceeding the analyst estimate of $0.05, reflecting a notable improvement in profitability.
- Strong Cash Reserves: At year-end, Zevra held $238.9 million in cash, cash equivalents, and securities, which is expected to be sufficient to execute its strategic priorities independently of capital markets, enhancing financial stability.
- Market Sentiment Shift: Retail sentiment around ZVRA stock on Stocktwits shifted from 'bullish' to 'extremely bullish', with analysts unanimously rating it 'Buy' and a 12-month price target of $22.54, indicating strong market confidence in its growth prospects.
See More
Zevra Therapeutics Surges 21% After Strong Earnings Report
- Strong Earnings: Zevra Therapeutics reported over $34 million in net revenue for Q4 2025, a 44% increase year-over-year, significantly exceeding analysts' expectations of $28 million, indicating robust market performance and growth potential.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a remarkable turnaround from a $35.7 million loss in the previous year, enhancing investor confidence in its financial health.
- Miplyffa Sales Surge: Miplyffa's net sales skyrocketed to over $87 million in the quarter, nearly ninefold growth compared to last year, reflecting strong market acceptance for treating Niemann-Pick disease and driving overall company performance.
- International Market Potential: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating significant expansion potential in international markets, which could further bolster the company's growth trajectory.
See More
Zevra Therapeutics Reports 44% Revenue Growth and Profitability
- Financial Performance Exceeds Expectations: Zevra Therapeutics reported over $34 million in net revenue for Q4, reflecting a 44% year-over-year increase that significantly surpassed analyst expectations of $28 million, indicating robust market performance and a notable improvement in profitability.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a substantial turnaround from a loss of $35.7 million in the same quarter last year, which enhances investor confidence in the company's financial health.
- Miplyffa Drug Success: Miplyffa's net sales soared to nearly $87 million this quarter, nearly ninefold growth compared to last year, with coverage reaching 68% of lives, demonstrating strong market acceptance and potential in treating Niemann-Pick disease.
- International Market Opportunities: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating that the drug's success in the U.S. could be replicated in the European market, further expanding the company's growth prospects.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
Zevra Therapeutics Stock Rises 19% Following GeneDx Testing Program Announcement
- Significant Stock Surge: Zevra Therapeutics (ZVRA) shares have surged approximately 19% in Tuesday morning trading, currently priced at $10.83, reflecting an 18.75% increase from the opening price of $9.12, indicating strong market enthusiasm for the new initiative.
- New Genetic Testing Initiative: GeneDx has announced a collaboration with Zevra to launch a new genetic testing program aimed at expanding access to exome sequencing for Niemann-Pick Disease type C, assisting clinicians in confirming diagnoses and guiding clinical decisions.
- Trading Range Insights: Over the past year, Zevra's stock has fluctuated between $6.19 and $13.16, with the current price nearing its yearly high, showcasing investor confidence in the company's growth potential moving forward.
- Patient Benefits: Through this program, eligible patients in the United States will gain access to genomic testing to help confirm or rule out a diagnosis of Niemann-Pick Disease type C, thereby enhancing treatment outcomes and quality of life for patients.
See More
U.S. Stocks Rise as NIO Reports Strong Earnings
- Quarterly Revenue Surge: NIO reported quarterly revenue of 34.65 billion yuan ($4.95 billion), reflecting a year-over-year increase of 75.9% and a sequential rise of 59.0%, surpassing the analyst consensus estimate of $4.61 billion, indicating robust market demand and sales growth potential.
- Significant Earnings Improvement: The company's adjusted earnings came in at 0.29 yuan (4 cents) per ADS, a remarkable turnaround from a loss of 3.17 yuan per ADS a year earlier, exceeding expectations for a 5-cent loss, showcasing effective cost control and enhanced profitability.
- Stock Price Rally: Following the earnings report, NIO shares surged 10.6% to $5.47, reflecting investor optimism regarding the company's future growth prospects and potentially attracting more institutional investor interest.
- Overall Market Performance: The U.S. stock market rose overall, with the Dow Jones index gaining around 200 points on Tuesday, indicating increased confidence in economic recovery, which may provide a favorable investment environment for NIO and other tech stocks.
See More
